Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET)

NCT04858867 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT04858867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET)
Lead sponsor
Leiden University Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
January 10, 2022
Completion date
June 1, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer